Skip to main content
Clinical Trials/NCT07324239
NCT07324239
Not yet recruiting
Not Applicable

Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized Controlled Trial

Middle East University1 site in 1 country60 target enrollmentStarted: January 2, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Middle East University
Enrollment
60
Locations
1
Primary Endpoint
Pelvic pain

Overview

Brief Summary

Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.

Detailed Description

Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups.

Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments.

Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments.

Evaluation Procedures:

  1. Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index.
  2. Sleep quality using the Pittsburgh Sleep Quality Index.
  3. Erectile function using the International Index of Erectile Function.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
30 Years to 50 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months.
  • Ages will be ranged from 30 to 50 years old.

Exclusion Criteria

  • Urinary and seminal infections.
  • Recent parenteral steroid administration.
  • Prior prostate or pelvic surgery.
  • Lower urinary tract disorders such as bladder stones.
  • Implanted electronic devices as pacemakers.
  • Sensory loss over the perineum.

Arms & Interventions

TECAR therapy group

Active Comparator

Intervention: TECAR therapy (Device)

Control group

Sham Comparator

Intervention: Sham TECAR therapy (Device)

Outcomes

Primary Outcomes

Pelvic pain

Time Frame: Baseline and 8 weeks later

Pain will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index

Secondary Outcomes

  • Quality of life of men(Baseline and after 8 weeks)

Investigators

Sponsor
Middle East University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Saher Lotfy El Gayar

Assistant Professor of Physical Therapy

Middle East University

Study Sites (1)

Loading locations...

Similar Trials